Harvard Bioscience (HBIO) Total Debt (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Debt data on file, last reported at $36.2 million in Q1 2026.

• Total Debt for Q1 2026 came in at $36.2 million, up 0.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.2 million (up 0.7% YoY), and the FY2025 annual result was $35.9 million, down 2.94% from the prior year.
• Total Debt rose to $36.2 million in Q1 2026 per HBIO's latest filing, from $35.9 million in the prior quarter.
• Over five years, Total Debt peaked at $49.3 million in Q3 2022 and troughed at $34.0 million in Q3 2025.
• A 5-year average of $39.8 million and a median of $37.0 million in 2024 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2023: Total Debt rose 12.38% in 2022, then declined 21.91% in 2023.
• A 5-year view of Total Debt shows it stood at $46.8 million in 2022, then decreased by 21.91% to $36.6 million in 2023, then gained by 1.07% to $37.0 million in 2024, then fell by 2.94% to $35.9 million in 2025, then rose by 0.95% to $36.2 million in 2026.
• Business Quant data shows HBIO's Total Debt at $36.2 million in Q1 2026, $35.9 million in Q4 2025, and $34.0 million in Q3 2025.